Table 1.
Baseline characteristics of included patients
| Characteristics | All | First prescription by general practitioner | First prescription by urologist |
|---|---|---|---|
| N (%) | 12,191 | 6772 (55.5) | 5419 (44.5) |
| Age, mean ± SD | 65.3 ± 12.2 | 65.8 ± 11.8 | 64.6 ± 12.7 |
| Age group, N (%) | |||
| 30–49 | 1281 (10.5) | 554 (8.2) | 727 (13.4) |
| 50–59 | 2483 (20.4) | 1436 (21.2) | 1047 (19.3) |
| 60–69 | 3836 (31.5) | 2219 (32.8) | 1617 (42.2) |
| 70–79 | 3004 (24.6) | 1645 (24.3) | 1359 (25.1) |
| 80–100 | 1587 (13.0) | 918 (13.6) | 669 (12.3) |
| α-Blocker, N (%) | |||
| Alfuzosin | 3175 (26.0) | 2227 (32.9) | 948 (17.5) |
| Tamsulosin | 8981 (73.7) | 4535 (67.0) | 4445 (82.0) |
| Terazosin | 8 (0.1) | 5 (0.1) | 3 (0.1) |
| Silodosin | 27 (0.2) | 5 (0.1) | 22 (0.4) |
| Combination therapy, n (%) | 935 (7.7) | 241 (3.6) | 694 (12.8) |
| Median duration of therapy, days (IQR) | 180 (45–857) | 210 (45–735) | 150 (45–735) |